Investor smiles about new experimental cancer drugs and an aggressive play for the animal health market in China turned to frowns after Lilly disclosed deep cuts to its U.S. sales force.
The Indianapolis pharmaceuticals giant said Thursday that it would lay off hundreds of U.S. sales reps, as it prepares for the loss of patent protection on two of its best-selling drugs.
Lawyers for a security company being sued in the theft of $60 million worth of pharmaceuticals from an Eli Lilly and Co. warehouse in Connecticut say there's no proof the thieves used a report it prepared about security weaknesses in the building.
The idea behind the program, which starts in September, is that doctors can no longer leave the business aspect of their jobs to the finance guys while maintaining their integrity as healers.
A federal lawsuit contends that thieves who broke into an Eli Lilly and Co. warehouse in Connecticut three years ago and stole more than $60 million worth of drugs obtained a copy of a report that revealed weaknesses in the building's security system.
The new investment will bring the plant’s total price tag to $320 million as the pharmaceutical giant seeks to increase production of insulin and related products.
Indiana’s laws requiring hospitals to release price information are woefully inadequate, according to a report by two health insurance reform groups. Indiana was among 29 states to receive an "F" grade.
Johnson & Johnson, the world’s largest seller of health-care products, won approval for the first in a new family of diabetes drugs, giving them the edge against rivals including Eli Lilly and Co. that are developing similar medicines.
Eli Lilly and Co. said Monday that it has submitted a new type 2 diabetes treatment it is developing with German drugmaker Boehringer Ingelheim to the Food and Drug Administration.
A central Indiana REIT that went public in 2012 has agreed to buy 13 senior housing and care facilities in three states, growing its asset value by 50 percent.
Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for years, steep price declines.
Shares of several pharmaceutical companies that make diabetes medicines, including Eli Lilly, fell after U.S. regulators warned they are looking into potential risks of drugs in two classes of diabetes treatments.
More than two dozen of the world's largest pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., have agreed to provide funding and other support to Interpol's battle against counterfeit prescription drugs.
Eli Lilly and Co. and five other big drugmakers avoided paying $7 billion in U.S. taxes last year by shifting their profits overseas. The strategy has drawn the ire of some legislators.
Eli Lilly and Co. has sued Roche Holding AG’s Genentech unit, asking a court to invalidate patents used to make treatments for cancer and autoimmune diseases.
Endocyte Inc. saw its shares fall nearly 7 percent Tuesday morning after the drug development firm announced that its application for U.S. approval of a cancer drug could be delayed another 10 months.
What are Zeke Turner's top five strategies for keeping his work week under 40 hours? Do you really need work e-mail on your smart phone? What's it like to take a company public? The real estate exec has answers.
Researchers suspect the sex hormone known to increase libido and musculature could also play a role in preventing a form of diabetes that tends to strike later in life and afflicts more than 330 million people worldwide.
Diagnostic products maker Qiagen NV said Wednesday that it will work with Eli Lilly and Co. to develop new tests that could identify patients who could be helped by Lilly’s drugs.
Eli Lilly said it is halting testing of experimental drug tabalumab because the studies show the medicine is not effective. The company said it expects to take a $50 million charge in the first quarter related to the research expenses from the drug.
